531739 — Gennex Laboratories Income Statement
0.000.00%
Last trade - 00:00
- IN₹3.66bn
- IN₹3.65bn
- IN₹656.03m
- 44
- 20
- 80
- 44
R2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 558 | 556 | 596 | 612 | 656 |
Cost of Revenue | |||||
Gross Profit | 231 | 220 | 239 | 231 | 257 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 528 | 534 | 540 | 566 | 618 |
Operating Profit | 30.4 | 22.4 | 56.5 | 45.9 | 37.7 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 30.3 | 25.5 | 50.6 | 50.9 | 63.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | 22.2 | 18.6 | 40.4 | 39.2 | 49.2 |
Net Income Before Extraordinary Items | |||||
Net Income | 22.2 | 18.6 | 40.4 | 39.2 | 49.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 22.2 | 18.6 | 40.4 | 39.2 | 49.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.167 | 0.134 | 0.327 | 0.296 | 0.337 |